Lung cancer screening progress in Canada

Current state of lung cancer in Canada

Key takeaway

Lung cancer is the leading cause of cancer death in Canada, placing a growing burden on individuals, families, the healthcare system and the economy. While commercial tobacco* control efforts have helped reduce smoking rates and prevent lung cancer, expanding screening and increasing access to integrated smoking cessation supports remain critical to decreasing this burden.(1-3)

Lung cancer continues to have a major impact on people in Canada and the healthcare system. It is the leading cause of cancer-related death, carries high healthcare costs and disproportionately affects First Nations, Inuit, Métis and populations experiencing inequities. (1, 4)

A range of factors contribute to an individual’s risk of developing lung cancer, with smoking remaining the most significant risk factor. (5,6) Smoking is responsible for nearly three-quarters (72 per cent) of lung cancer cases,(5, 7) and as of 2024, 11 per cent of Canadians aged 18 and older currently smoke. (8)

Lung cancer screening detects cancer earlier, improving patient outcomes and quality of life while supporting a more sustainable healthcare system. (9, 10, 2) Tracking participation and stage at diagnosis in screening helps measure program success, identify gaps in access, and ensures more people benefit from screening, smoking cessation support and high-quality care. (11)

What are the impacts of lung cancer?

Economic

  • Direct health system cost of lung cancer (2024) projected to be $5.6 billion, approximately $190,000 over a patient’s lifetime. (2)
  • Societal costs, such as healthcare expenses, out-of-pocket costs, lost time, and other costs experienced by people with cancer and their caregivers, are $6.8 billion (2024), and projected to increase by 31 per cent, rising to $8.9 billion in 2034. (2)

Health outcomes

  • Survival differs dramatically by the stage at which a patient is diagnosed. Only 3 per cent of patients diagnosed at stage IV are alive five years after diagnosis, compared with more than 60 per cent of those diagnosed at stage I. (12, 13)
  • About 70 per cent of lung cancers are diagnosed at stage III or IV. Lung cancer screening aims to diagnosis lung cancers at an earlier stage. (12, 13)

Equity

  • Lower-income and rural or remote populations face higher smoking rates and a higher burden of lung cancer including increased incidence, later-stage diagnosis, lower access to curative treatment, and poorer survival outcomes.(14)
  • First Nations, Inuit and Métis people are more likely to have lower incomes and live in rural or remote communities and are therefore even more likely to be disproportionately affected by these inequities.(14) Lower income may affect the ability of individuals to access treatment, and care for those affected by lung cancer.

Lung cancer remains the leading cause of cancer death, and in 2026 it is expected to account for approximately one in five cancer deaths in Canada.(1)


*Tobacco refers to commercial tobacco products, not traditional or sacred tobacco. Traditional or sacred tobacco is used by some First Nations or Métis communities in ceremonial or sacred rituals for healing and purifying.

  1. Canadian Cancer Society. Lung and bronchus cancer statistics [Internet]. Toronto (ON): Canadian Cancer Society; 2026 Apr [cited 2026 Aug 7]. Available from: https://cancer.ca/en/cancer-information/cancer-types/lung/statistic
  2.  Canadian Cancer Statistics Advisory Committee, in collaboration with the Canadian Cancer Society, Statistics Canada, and the Public Health Agency of Canada. Canadian Cancer Statistics: A 2024 special report on the economic impact of cancer in Canada [Internet]. Toronto (ON): Canadian Cancer Society; 2024 Dec [cited 2026 Aug 7]. Available from: https://cancer.ca/en/cancer-information/resources/publications/canadian-cancer-statistics-a-2024-special-report-on-the-economic-impact-of-cancer-in-canada0835-2976-2024-special-report-en.pdf
  3. Canadian Partnership Against Cancer. Smoking cessation in cancer care across Canada, 2022-23: Impact of a pan-Canadian initiative [Internet]. Toronto (ON): Canadian Partnership Against Cancer; 2023 [cited 2026 Aug 7]. Available from: https://www.partnershipagainstcancer.ca/topics/smoking-cessation-cancer-care-2022-2023
  4. Canadian Partnership Against Cancer. Lung cancer and equity: A focus on income and geography [Internet]. Toronto (ON): Canadian Partnership Against Cancer; 2020 Nov [cited 2026 Aug 7]. Available from: https://www.partnershipagainstcancer.ca/topics/lung-cancer-equity/
  5. Health Canada. Tobacco and lung cancer [Internet]. Ottawa (ON): Government of Canada; 2023 Mar [cited 2026 Aug 10]. Available from: https://www.canada.ca/en/health-canada/services/health-concerns/tobacco/legislation/tobacco-product-labelling/smoking-lung-cancer.htm
  6. Canadian Cancer Society. Risks for lung cancer [Internet]. Toronto (ON): Canadian Cancer Society; 2024 Nov[cited 2026 Aug 10]. Available from: https://cancer.ca/en/cancer-information/cancer-types/lung/risks
  7. Poirier AE, Ruan Y, Grevers X, Walter SD, Villeneuve PJ, Friedenreich CM, et al. Estimates of the current and future burden of cancer attributable to active and passive tobacco smoking in Canada. Prev Med. 2019 May;122:9-19. doi: 10.1016/j.ypmed.2019.03.015
  8. Public Health Agency of Canada. Data tool: Tobacco and Vaping Use in Canada [Internet]. Ottawa (ON): Government of Canada; 2026 Jul [cited 2026 Aug 10]. Available from: https://health-infobase.canada.ca/substance-use/tobacco/surveillance
  9. Lam S, Bai C, Baldwin DR, Chen Y, Connolly C, de Koning H, et al. Current and future perspectives on computed tomography screening for lung cancer: a roadmap from 2023 to 2027 from the International Association for the Study of Lung Cancer. J Thorac Oncol. 2024 Jan;19(1):36-51. doi:10.1016/j.jtho.2023.07.019.
  10. Canadian Cancer Society. Screening for lung cancer [Internet]. Toronto (ON): Canadian Cancer Society; 2025 [cited 2026 Aug 7]. Available from: https://cancer.ca/en/cancer-information/cancer-types/lung/screening
  11. Tammemägi MC, Borondy-Kitts A, Field JK, Lam, S. Kazerooni EA, Huber RM. Lung cancer screening program quality indicators: review and recommendations: an International Association for the Study of Lung Cancer Delphi process study. J Thorac Oncol. 2025 Jul;20(7):871-883. Available from: https://www.jto.org/article/S1556-0864(25)00052-8/fulltext
  12. Ellison LF, Saint-Jacques N. Five-year cancer survival by stage at diagnosis in Canada. Health Rep [Internet]. 2023 Jan ;34(1):3-15 [cited 2026 Aug 10]. Available from: https://www150.statcan.gc.ca/n1/pub/82-003-x/2023001/article/00001-eng.htm. doi:10.25318/82-003-x202300100001-eng
  13. Canadian Cancer Statistics Advisory Committee, in collaboration with the Canadian Cancer Society, Statistics Canada, and the Public Health Agency of Canada. Canadian Cancer Statistics 2025 [Internet]. Toronto (ON): Canadian Cancer Society; 2025 [cited 2026 Aug 10]. Available from: https://cancer.ca/en/cancer-information/resources/publications/canadian-cancer-statistics-2025
  14. Canadian Partnership Against Cancer. Lung cancer and equity: A focus on income and geography [Internet]. Toronto (ON): Canadian Partnership Against Cancer; 2020 [cited 2026 Aug 10]. Available from: https://www.partnershipagainstcancer.ca/wp-content/uploads/2020/11/Lung-cancer-and-equity-report-EN.pdf